Ascendis Pharma is applying its innovative TransCon technology, which combines the benefits of prodrug and sustained-release technologies, to develop a pipeline of best‐in‐class therapeutics that address significant unmet medical needs. The TransCon technology can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs that provide for the predictable and sustained releas...
Ascendis Pharma is applying its innovative TransCon technology, which combines the benefits of prodrug and sustained-release technologies, to develop a pipeline of best‐in‐class therapeutics that address significant unmet medical needs. The TransCon technology can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.